Top

Drugs - Real World Outcomes

Published in:

Open Access 01-06-2017 | Original Research Article

Characterization of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis Among Patients Admitted to Kenyatta National Hospital: A Retrospective Cross-Sectional Study

Authors: Kenneth Irungu, David Nyamu, Sylvia Opanga

Published in: Drugs - Real World Outcomes | Issue 2/2017

Abstract

Background

Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous reactions. There is scant literature on the characteristics and causes of these conditions in Kenyatta National Hospital.

Objective

The aim of this study was to determine the prevalence, risk factors, and etiologies of SJS/TEN among patients admitted to Kenyatta National Hospital.

Methods

A retrospective cross-sectional study was done to find the characteristics and causes of severe cutaneous reactions among patients admitted to Kenyatta National Hospital. Universal sampling was employed, whereby all 115 patients with severe cutaneous reactions between June 2006 and June 2016 were studied. Information collected included participants’ sociodemographic variables, clinical characteristics of the disease, and the possible triggers. Data were analyzed using STATA version 13 at p ≤ 0.05.

Results

The mean age of patients was 31 years (±20). Low case numbers precluded statistically significant results; however, females represented 59.1% of patients, and 46.1% of patients were diagnosed between the ages of 21 and 40 years. SJS occurred in 47% of patients followed by TEN in 33.9% and SJS/TEN overlap in 19.1%. Drugs were determined to be the causative agent in 94.8% of the severe cutaneous reactions followed by infectious agents at 5.2%, principally HIV, herpes simplex virus 1, and mycoplasma. The most common drugs implicated were sulfonamides (26.1%) and nevirapine (15.7%).

Conclusion

Numerically, SJS was the most common subtype of SJS/TEN in Kenyatta National Hospital and was usually attributed to use of drugs, especially sulfonamides. Severe cutaneous reactions were observed more frequently in females and in patients aged between 21 and 40 years, indicating that emphasizing surveillance and medication counselling in these patient populations could be beneficial.

Roujeau J, Kelly J, Naldi L, Rzany B, Stern R, Anderson T, et al. Medication use and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600–7.CrossRefPubMed

Harr T, French L. Toxic epidermal necrolysis and Stevens–Johnson syndrome. Orphanet J Rare Dis. 2010;5:39.CrossRefPubMedPubMedCentral

Patel T, Thakkah S, Sharmar D. Cutaneous adverse drug reactions in Indian population: a systematic review. Indian Dermatol Online J. 2014;5:76–86.CrossRef

Schopf E, Stuhmer A, Rzany B, Victor N, Zentgraf R, Kapp J. Toxic epidermal necrolysis and Stevens–Johnson syndrome: an epidemiologic study from West Germany. Arch Dermatol. 1991;127:839–42.CrossRefPubMed

Yamane Y, Matsukura S, Watanabe Y, Yamaguchi Y. Retrospective analysis of Stevens Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients: treatment and outcome. Allergol Int. 2016;65:74–81.CrossRefPubMed

Saka B, Barro-traore F, Atadokpe FA, Niamba PA, Ade H, Pitche VP, et al. Tropical medicine rounds Stevens–Johnson syndrome and toxic epidermal necrolysis in sub-Saharan Africa: a multicentric study in four countries. Int J Dermatol. 2013;52:575–9.CrossRefPubMed

Clinard V. Drug-induced skin disorders. In: US Pharmacist. 2012. https://www.uspharmacist.com/article/drug-induced-skin-disorders. Accessed 10 Dec 2015.

Roujeau J, Stern R. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331:1272–85.CrossRefPubMed

Naranjo C, Busto U, Sellers E, Sandor P, Ruiz I, Roberts E, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45.CrossRefPubMed

10.

Chan H-L. The incidence of erythema multiforme, Stevens–Johnson syndrome, and toxic epidermal necrolysis. Arch Dermatol Am Med Assoc. 1990;126:43.CrossRef

11.

Yamane Y, Aihara M, Ikezawa Z. Analysis of Stevens–Johnson syndrome and toxic epidermal necrolysis in Japan from 2000 to 2006. Allergol Int. 2007;56:419–25.CrossRefPubMed

12.

Kizito M. Assessment of the patient factors impacting on oral anticoagulation therapy among adult outpatients at Kenyatta national hospital. [MPharm Thesis]. University of Nairobi, 2015.

13.

Bastuji-garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau J. Clinical classification of cases of toxic epidermal necrolysis, Stevens–Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129:92–6.CrossRefPubMed

14.

Haddad C, Sidoroff A, Kardaun SH, Mockenhaupt M, Creamer D, Dunant A, et al. Stevens–Johnson syndrome/toxic epidermal necrolysis: are drug dictionaries correctly informing physicians regarding the risk? Drug Saf. 2013;36:681–6.CrossRefPubMed

15.

Levi N, Bastuji-Garin S, Mockenhaupt M, Roujeau J-C, Flahault A, Kelly JP, et al. Medications as risk factors of Stevens–Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics. 2009;123:297–304.CrossRef

16.

Sontheimer R, Garibaldi R, Gerald G, Krueger M. Stevens–Johnson syndrome associated with Mycoplasma pneumoniae infections. Arch Dermatol. 1978;114:241–4.CrossRefPubMed

17.

Garcia-Doval I, LeCleach L, Bocquet H, Otero X, Roujeau J-C. Toxic epidermal necrolysis and Stevens–Johnson syndrome. Arch Dermatol Am Med Assoc. 2000;136:323–7.

18.

Kilmarx PH. Global epidemiology of HIV. Curr Opin I HIV AIDS. 2009;4:240–6.CrossRefPubMed

19.

Malaria Control Programme. Epidemiology of malaria in Kenya. Afr J Med Pract. 1994;1:5–6.

20.

Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, et al. Stevens–Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Investig Dermatol. The Society for Investigative Dermatology, Inc. 2008;128:35–44.

21.

Wafula E, Abinya N, Karanja J, Kaseje D, Musoke R. Clinical guidelines for management and referral of common conditions at levels 4–6 hospitals, vol. III. Nairobi: Ministry of Medical Services and Ministry of Public Health and Sanitation; 2009.

Title: Characterization of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis Among Patients Admitted to Kenyatta National Hospital: A Retrospective Cross-Sectional Study
Authors: Kenneth Irungu
David Nyamu
Sylvia Opanga
Publication date: 01-06-2017
Publisher: Springer International Publishing
Published in: Drugs - Real World Outcomes / Issue 2/2017
Print ISSN: 2199-1154
Electronic ISSN: 2198-9788
DOI: https://doi.org/10.1007/s40801-017-0105-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Characterization of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis Among Patients Admitted to Kenyatta National Hospital: A Retrospective Cross-Sectional Study

Abstract

Background

Objective

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2017

Risk of Hip Fracture in Older People Using Selective Serotonin Reuptake Inhibitors and Other Psychoactive Medicines Concurrently: A Matched Case–Control Study in Australia

Spontaneously Reported Adverse Reactions for Herbal Medicinal Products and Natural Remedies in Sweden 2007–15: Report from the Medical Products Agency

Characterisation of Drug-Related Problems and Associated Factors at a Clinical Pharmacist Service-Naïve Hospital in Northern Sweden

In the Real-World, Kids Use Medications and Devices

Treatment Satisfaction During Sublingual Immunotherapy with a Five-Grass Pollen Tablet for Allergic Rhinoconjunctivitis: A Prospective, Non-Interventional Study